NCM
ONCT

Nantahala Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Nantahala Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-60,037
Closed -$2.04M – 127
2020
Q3 		$2.04M Buy
+60,037
New +$2.94M 0.06% 98

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nantahala Capital Management's ONCT Position: Q4 2020 in Review

Nantahala Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020, closing a stake of 60,037 shares — an estimated $2.04M sold.

Nantahala Capital Management first reported a position in ONCT in Q3 2020 and held it in 1 quarter. The position peaked at $2.04M in Q3 2020. 52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

  • Nantahala Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Nantahala Capital Management sold 60,037 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $2.04M.
  • Nantahala Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Nantahala Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.04M in Q3 2020.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Nantahala Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.